Filing Flows › West Pharmaceutical Services (WST) › Capital expenditures
West Pharmaceutical Services (WST) capital expenditures by quarter
West Pharmaceutical Services' capital expenditures were $39.1M in Q3 2026 (third quarter 2026), -9% from Q2 2026. Over the last 7 quarters it ranged from $39.1M (Q3 2026) to $76.1M (Q4 2025).
| Quarter | Capital expenditures | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $39.1M | -9% | -38% |
| Q2 2026 | $43.2M | +1% | -43% |
| Q1 2026 | $42.7M | -44% | -40% |
| Q4 2025 | $76.1M | +20% | — |
| Q3 2025 | $63.3M | -16% | — |
| Q2 2025 | $75.2M | +5% | — |
| Q1 2025 | $71.3M | — | — |
Q3 2026 at a glance
West Pharmaceutical Services, Q3 2026: revenue $874M (+9% year over year), operating margin 30.6%, net earnings $214M, operating cash flow $190M. The chart follows the revenue to costs, profit and cash.
Questions
What is West Pharmaceutical Services' capital expenditures?
West Pharmaceutical Services' capital expenditures were $39.1M in Q3 2026 (third quarter 2026), -9% from Q2 2026.
How has West Pharmaceutical Services' capital expenditures changed?
Over the last 7 quarters it ranged from $39.1M (Q3 2026) to $76.1M (Q4 2025).
Q3 2026 results → · How West Pharmaceutical Services makes money →